Markets
Tech
Media
Success
Video
Markets
Premarkets
Dow
After-Hours
Market Movers
Fear & Greed
World Markets
Investing
Markets Now
Before the Bell
Leading Indicator
Global Energy Challenge
Economy
Tracking America's Recovery
Energy
Tech
Innovate
Gadget
Mission: Ahead
Upstarts
Business Evolved
Work Transformed
Innovative Cities
Unhackable
Media
Reliable Sources
Success
Boss Files
Fresh Money
Cars
Homes
Biz + Leisure
Center Piece
Perspectives
Video
International
Switzerland
India
Davos
Passion to Portfolio
On: Germany
More
Newsletters
About Us
Accessibility and CC
U.S.
World
Politics
Business
Opinion
Health
Entertainment
Tech
Style
Travel
Sports
Video
Shop
VR
More...
Follow CNN Business
Do Not Sell
CRISPR Therapeutics AG
(NASDAQ:CRSP)
181.22
Delayed Data
As of Jan 25
-7.27
/
-3.86%
Today’s Change
32.30
Today
|||
52-Week Range
220.20
+18.36%
Year-to-Date
Quote
Profile
News
Charts
Forecasts
Financials
Shareholders
Competitors
Latest CRSP News
|
Press Releases
Where to Invest $1 Million Right Now
Jan 24 / MotleyFool.com - Paid Partner Content
Of Politics and Stock Prices
Jan 17 / MotleyFool.com - Paid Partner Content
A Deep Dive into ARK ETFs
Jan 20 / Zacks.com - Paid Partner Content
My Top Health Stock for 2021
Jan 16 / MotleyFool.com - Paid Partner Content
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics
Jan 20 / Zacks.com - Paid Partner Content
7 Stocks Riding 3 Unstoppable Trends That Will Make You Richer in 2021 (and Beyond)
Jan 16 / MotleyFool.com - Paid Partner Content
Beam, SpringWorks Biggest Gainers on BioSpace List
Jan 19 / GuruFocus News - Paid Partner Content
2 Biotech Stocks That Could Double Your Money
Jan 16 / MotleyFool.com - Paid Partner Content
CRISPR (CRSP) Up More Than 80% in Past 3 Months: Here's Why
Jan 19 / Zacks.com - Paid Partner Content
5 Top-Performing ARK ETFs Worth Your Attention Now
Jan 13 / Zacks.com - Paid Partner Content
Editas (EDIT) Up More Than 100% in Past 3 Months: Here's Why
Jan 18 / Zacks.com - Paid Partner Content
Editas (EDIT) Gets FDA Nod to Begin Safety Study on EDIT-301
Jan 12 / Zacks.com - Paid Partner Content